{
    "clinical_study": {
        "@rank": "149848", 
        "arm_group": [
            {
                "arm_group_label": "Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B."
            }, 
            {
                "arm_group_label": "Arm B (trametinib)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized phase II/III trial studies how well trametinib works and compares it to\n      standard treatment with either letrozole, tamoxifen citrate, paclitaxel, pegylated liposomal\n      doxorubicin hydrochloride, or topotecan hydrochloride in treating patients with low-grade\n      ovarian cancer or peritoneal cavity cancer that has come back, become worse, or spread to\n      other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of\n      the enzymes needed for cell growth. It is not yet known whether trametinib is more effective\n      than standard therapy in treating patients with ovarian or peritoneal cavity cancer."
        }, 
        "brief_title": "Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer", 
        "condition": [
            "Ovarian Papillary Serous Carcinoma", 
            "Ovarian Serous Cystadenocarcinoma", 
            "Recurrent Ovarian Epithelial Cancer", 
            "Recurrent Primary Peritoneal Cavity Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Cystadenocarcinoma", 
                "Ovarian Neoplasms", 
                "Peritoneal Neoplasms", 
                "Cystadenocarcinoma, Serous", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To estimate the progression-free survival (PFS) hazard ratio of trametinib compared to\n      that of \"commercially available therapies\" consisting of one of five commercially available\n      agents in women with recurrent low-grade serous carcinoma of the ovary or peritoneum\n      previously treated with platinum-based chemotherapy.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine the nature, frequency and maximum degree of toxicity as assessed by Common\n      Terminology Criteria for Adverse Events (CTCAE) version (v)4 for each treatment arm.\n\n      II. To determine the quality of life, as assessed by the Functional Assessment of Cancer\n      Therapy-Ovarian (FACT-O).\n\n      III. To compare trametinib to the control arm with regard to patients' self-reported acute\n      (up to post-cycle 6) quality of life as measured by the FACT-O-Trial Outcome Index (TOI).\n\n      IV. To compare trametinib to the control arm with regard to patients' self-reported acute\n      (up to post-cycle 6) neurotoxicity as measured by the FACT-Gynecologic Oncology Group\n      (GOG)-Neurotoxicity (NTX).\n\n      V. To estimate the objective response rate (RR) of patients in each treatment arm.\n\n      TERTIARY OBJECTIVES:\n\n      I. To estimate the overall survival (OS) of patients in each treatment arm. II. To estimate\n      the tumor response rate in patients receiving trametinib after crossover from standard of\n      care.\n\n      III. To estimate the PFS in patients receiving trametinib after crossover from standard of\n      care.\n\n      IV. To compare trametinib to \"endocrine standard therapy\" (i.e., letrozole, tamoxifen) with\n      regard to patients' self-reported acute quality of life and neurotoxicity, as measured by\n      the FACT-O-TOI, and FACT-GOG-NTX, respectively.\n\n      V. To examine deoxyribonucleic acid (DNA) isolated from formalin-fixed, paraffin-embedded\n      sections of tissue from primary diagnosis, recurrence, and fine needle aspiration/core\n      biopsies with next generation sequencing mutational analyses of genes in the\n      mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)/v-akt\n      murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycin (mTOR) pathways\n      and to explore their relationship with tumor response in patients treated with trametinib.\n      (Translational research objectives) VI. To examine protein levels of estrogen receptor (ER),\n      progesterone receptor (PR), phosphorylated (p)mitogen-activated protein kinase 1 (ERK), and\n      dual specificity phosphatase 6 (DUSP6) and explore their relationship with tumor response in\n      patients treated with trametinib. (Translational research objectives) VII. To identify\n      transcriptional signatures by ribonucleic acid sequencing (RNAseq) that will predict\n      mitogen-activated protein kinase kinase (MEK) addiction and sensitivity to trametinib.\n      (Translational research objectives) VIII. To conduct studies of specific genes in cell-free\n      DNA in plasma of patients and to explore their relationship with tumor response to\n      trametinib. (Translational research objectives) IX. To examine the pharmacokinetics of\n      trametinib. (Translational research objectives)\n\n      OUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\n      ARM A: Patients receive clinician's choice of either letrozole orally (PO) once daily (QD)\n      on days 1-28, tamoxifen citrate PO twice daily (BID) on days 1-28, paclitaxel intravenously\n      (IV) over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride (PLD)\n      IV over 1 hour on day 1, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15.\n      Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n      Patients developing progressive disease may cross over to Arm B.\n\n      ARM B: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the\n      absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 3 months for 2 years,\n      every 6 months for 3 years, and then annually for 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with the following tumors are included in the study:\n\n               -  Patients initially diagnosed with low-grade serous ovarian or peritoneal\n                  carcinoma that recur as low-grade serous carcinoma (invasive micropapillary\n                  serous carcinoma or invasive grade I serous carcinomas as defined by GOG,\n                  Federation of Obstetricians and Gynecologists [FIGO], World Health Organization\n                  [WHO] or Silverberg)\n\n               -  Patients initially diagnosed with serous borderline ovarian or peritoneal\n                  carcinoma that recur as low-grade serous carcinoma (invasive micropapillary\n                  serous carcinoma or invasive grade I serous carcinomas as defined by GOG, FIGO\n                  WHO or Silverberg)\n\n          -  Patients must have documented low-grade serous carcinoma; confirmation must occur by\n             prospective pathology review prior to study entry; the prospective pathology review\n             must be done on tissue from the recurrent carcinoma\n\n          -  All patients must have measurable disease as defined by Response Evaluation Criteria\n             in Solid Tumors (RECIST) 1.1; measurable disease is defined as at least one target\n             lesion that can be accurately measured in at least one dimension (longest diameter to\n             be recorded); each lesion must be > 10 mm when measured by computed tomography (CT),\n             magnetic resonance imaging (MRI), or caliper measurement by clinical exam; or >= 20\n             mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when\n             measured by CT or MRI; all imaging studies must be performed within 28 days prior to\n             registration\n\n          -  Prior therapy\n\n               -  Patients must have recurred or progressed following at least one platinum-based\n                  chemotherapy regimen\n\n               -  Patients may have received an unlimited number of prior therapy regimens\n\n               -  Patients may not have received all of the five choices in the \"standard therapy\"\n                  arm\n\n          -  An image-guided fine needle aspiration/core biopsy of fresh tissue must be obtained\n             prior to randomization and submitted for translational research\n\n          -  Patients of childbearing potential must have a negative pregnancy test, cannot be\n             breast-feeding, and must agree to practice an effective means of birth control prior\n             to study entry, for the duration of study participation, and for four months after\n             dosing with trametinib ceases\n\n          -  Patients must have signed an approved informed consent and authorization permitting\n             release of personal health information\n\n          -  Patients must have a GOG performance status of 0 or 1\n\n          -  Able to swallow and retain orally-administered medication and does not have any\n             clinically significant gastrointestinal abnormalities that may alter absorption, such\n             as malabsorption syndrome or major resection of the stomach or bowels\n\n          -  Patients must have a left ventricular ejection fraction >= lower limit of normal by\n             echocardiogram (ECHO) or multigated acquisition scan (MUGA)\n\n          -  Creatinine clearance >= 50 mL/min\n\n          -  Bilirubin =< 1.5 times upper limit of normal\n\n          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times\n             upper limit of normal\n\n          -  Albumin >= 2.5 g/dL\n\n          -  Prothrombin time (PT) and activated partial thromboplastin time (APTT) =< 1.5 times\n             upper limit of normal\n\n          -  Neutrophil count >= 1.2 x 10^9/L\n\n          -  Platelet count >= 100 x 10^9/L\n\n          -  Hemoglobin >= 9.0 g/dL\n\n          -  If letrozole is selected as the control therapy, patients must be postmenopausal,\n             either following bilateral oophorectomy or at least 5 years after spontaneous\n             menopause; patients within 5 years of spontaneous menopause or who have had a\n             hysterectomy without bilateral oophorectomy must have postmenopausal luteinizing\n             hormone (LH) and follicle stimulating hormone (FSH) levels; patients on hormone\n             replacement therapy (HRT) must agree to withdrawal of hormone therapy before\n             letrozole is started\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for\n             nitrosoureas or mitomycin C) prior to entering the study or those who have not\n             recovered from adverse events due to agents administered more than 4 weeks earlier\n\n          -  If patients have had a potential index lesion radiated, it must have progressed post\n             radiation therapy to be used as a measurable eligibility lesion\n\n          -  Patients may not have received prior MEK, v-Ki-ras2 Kirsten rat sarcoma viral\n             oncogene homolog (KRAS), or v-raf murine sarcoma viral oncogene homolog B1 (BRAF)\n             inhibitor therapy\n\n          -  Current use of a prohibited medication; the following medications or non-drug\n             therapies are prohibited:\n\n               -  Patients may not be receiving any other anti-cancer or investigational agents\n\n               -  The concurrent use of all herbal supplements is prohibited during the study\n                  (including, but not limited to St. John's Wort, kava, ephedra [ma huang], gingko\n                  biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)\n\n          -  Patients with known leptomeningeal or brain metastases or spinal cord compression\n             should be excluded from this clinical trial\n\n          -  Patients with a bowel obstruction or any other gastrointestinal condition that might\n             affect absorption of the oral drug should be excluded; this would include patients\n             with inability to swallow and retain orally-administered medication, malabsorption\n             syndrome, or those with a major resection of the stomach or bowels\n\n          -  Patients with a history of interstitial lung disease or pneumonitis\n\n          -  Patients with a previous or current malignancy at other sites should be excluded,\n             with the exception of:\n\n               -  Curatively treated local tumors such as carcinoma-in-situ of the cervix, basal\n                  or squamous cell carcinoma of the skin\n\n               -  Tumors for which no relapse has been observed within 5 years\n\n          -  Patients with active hepatitis B or C; human immunodeficiency virus (HIV) infected\n             patients with adequate CD4 counts (> 350 cells/mm3) will be eligible; HIV-positive\n             patients on combination antiretroviral therapy are ineligible\n\n          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs\n             chemically related to the study drug, or excipients, or to dimethyl sulfoxide (DMSO),\n             or to Cremophor EL (polyoxyethylated castor oil); please note, exclusion for\n             Cremophor is unnecessary unless paclitaxel is the only agent available and the\n             patient randomizes to the conventional therapy option\n\n          -  Patients with a history or evidence of cardiovascular risk, including any of the\n             following:\n\n               -  Left ventricular ejection fraction (LVEF) < lower limit of normal (LLN)\n\n               -  Bazett's corrected QT (QTcB) >= 480 msec\n\n               -  History or evidence of current clinically significant uncontrolled arrhythmias\n\n               -  Exception: Subjects with controlled atrial fibrillation for > 30 days prior to\n                  randomization are eligible\n\n               -  History of (within 6 months prior to randomization) acute coronary syndromes\n                  (including myocardial infarction and unstable angina), coronary angioplasty, or\n                  stenting\n\n               -  History or evidence of current >= class II congestive heart failure as defined\n                  by New York Heart Association (NYHA)\n\n               -  Treatment refractory hypertension defined as a blood pressure of systolic > 140\n                  mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive\n                  therapy\n\n               -  Patients with intra-cardiac defibrillators or permanent pacemakers\n\n               -  Known cardiac metastases\n\n          -  Patients with a history or current evidence/risk of retinal vein occlusion (RVO) or\n             central serous retinopathy (CSR):\n\n               -  History of RVO or CSR, or predisposing factors to RVO or CSR (e.g., uncontrolled\n                  glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled\n                  diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes)\n\n               -  Visible retinal pathology as assessed by ophthalmic exam that is considered a\n                  risk factor for RVO or CSR, such as:\n\n                    -  Evidence of new optic disc cupping\n\n                    -  Intraocular pressure > 21 mm Hg as measured by tonography\n\n                    -  Evidence of new visual field defects\n\n          -  Patients with any psychological, familial, sociological, or geographical condition\n             that may potentially hamper compliance with the study protocol and follow-up schedule\n\n          -  Patients who require use of a concomitant medication that can prolong the QT interval"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101788", 
            "org_study_id": "NCI-2014-00629", 
            "secondary_id": [
                "NCI-2014-00629", 
                "GOG-0281", 
                "GOG-0281", 
                "U10CA027469", 
                "U10CA180868"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)", 
                "description": "Given PO", 
                "intervention_name": "letrozole", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CGS 20267", 
                    "Femara", 
                    "LTZ"
                ]
            }, 
            {
                "arm_group_label": "Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)", 
                "description": "Given PO", 
                "intervention_name": "tamoxifen citrate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Nolvadex", 
                    "TAM", 
                    "tamoxifen", 
                    "TMX"
                ]
            }, 
            {
                "arm_group_label": "Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)", 
                "description": "Given IV", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Anzatax", 
                    "Asotax", 
                    "TAX", 
                    "Taxol"
                ]
            }, 
            {
                "arm_group_label": "Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)", 
                "description": "Given IV", 
                "intervention_name": "pegylated liposomal doxorubicin hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CAELYX", 
                    "Dox-SL", 
                    "DOXIL", 
                    "doxorubicin hydrochloride liposome", 
                    "LipoDox"
                ]
            }, 
            {
                "arm_group_label": "Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)", 
                "description": "Given IV", 
                "intervention_name": "topotecan hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "hycamptamine", 
                    "Hycamtin", 
                    "SKF S-104864-A", 
                    "TOPO"
                ]
            }, 
            {
                "arm_group_label": "Arm B (trametinib)", 
                "description": "Given PO", 
                "intervention_name": "trametinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GSK1120212", 
                    "JTP-74057", 
                    "Mekinist"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)", 
                    "Arm B (trametinib)"
                ], 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Other", 
                "other_name": "quality of life assessment"
            }, 
            {
                "arm_group_label": [
                    "Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)", 
                    "Arm B (trametinib)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)", 
                    "Arm B (trametinib)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Letrozole", 
                "Tamoxifen", 
                "Paclitaxel", 
                "Topotecan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Albert L. Pisani", 
                    "phone": "650-934-7000"
                }, 
                "facility": {
                    "address": {
                        "city": "Mountain View", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94040"
                    }, 
                    "name": "Palo Alto Medical Foundation-Gynecologic Oncology"
                }, 
                "investigator": {
                    "last_name": "Albert L. Pisani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30501"
                    }, 
                    "name": "Northeast Georgia Medical Center"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Mount Vernon", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62864"
                    }, 
                    "name": "Good Samaritan Regional Health Center"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Raymond S. Lord", 
                    "phone": "269-373-7458"
                }, 
                "facility": {
                    "address": {
                        "city": "Kalamazoo", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49007"
                    }, 
                    "name": "West Michigan Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Raymond S. Lord", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Bolivar", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65613"
                    }, 
                    "name": "Central Care Cancer Center-Carrie J Babb Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Branson", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65616"
                    }, 
                    "name": "CoxHealth Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Joplin", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64804"
                    }, 
                    "name": "Mercy Hospital-Joplin"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Joplin", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64804"
                    }, 
                    "name": "Freeman Health System"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Rolla", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65401"
                    }, 
                    "name": "Phelps County Regional Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Rolla", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65401"
                    }, 
                    "name": "Saint John's Clinic-Rolla-Cancer and Hematology"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141"
                    }, 
                    "name": "Saint John's Mercy Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63109"
                    }, 
                    "name": "Saint Louis Cancer and Breast Institute-South City"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65807"
                    }, 
                    "name": "CoxHealth South Hospital"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sherrijr@iora.org", 
                    "last_name": "Jay W. Carlson", 
                    "phone": "800-821-7532"
                }, 
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65804"
                    }, 
                    "name": "Mercy Hospital Springfield"
                }, 
                "investigator": {
                    "last_name": "Jay W. Carlson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kathryn.bartz@nmhs.org", 
                    "last_name": "Peter C. Morris", 
                    "phone": "402-354-7939"
                }, 
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68114"
                    }, 
                    "name": "Nebraska Methodist Hospital"
                }, 
                "investigator": {
                    "last_name": "Peter C. Morris", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Donna T. McNamara", 
                    "phone": "201-996-2879"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Hackensack University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Donna T. McNamara", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Belpre", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45714"
                    }, 
                    "name": "Strecker Cancer Center-Belpre"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Chillicothe", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45601"
                    }, 
                    "name": "Adena Regional Medical Center"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43215"
                    }, 
                    "name": "Columbus CCOP"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43214"
                    }, 
                    "name": "Columbus Oncology and Hematology Associates Inc"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43228"
                    }, 
                    "name": "Doctors Hospital"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43215"
                    }, 
                    "name": "Grant Medical Center"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43222"
                    }, 
                    "name": "Mount Carmel Health Center West"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43219"
                    }, 
                    "name": "The Mark H Zangmeister Center"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43214"
                    }, 
                    "name": "Riverside Methodist Hospital"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Delaware", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43015"
                    }, 
                    "name": "Grady Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Delaware", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43015"
                    }, 
                    "name": "Delaware Health Center-Grady Cancer Center"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Delaware", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43015"
                    }, 
                    "name": "Delaware Radiation Oncology"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Lancaster", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43130"
                    }, 
                    "name": "Lancaster Radiation Oncology"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Lancaster", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43130"
                    }, 
                    "name": "Fairfield Medical Center"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Marietta", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45750"
                    }, 
                    "name": "Marietta Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Mount Vernon", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43050"
                    }, 
                    "name": "Knox Community Hospital"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43055"
                    }, 
                    "name": "Licking Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43055"
                    }, 
                    "name": "Newark Radiation Oncology"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Portsmouth", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45662"
                    }, 
                    "name": "Southern Ohio Medical Center"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45505"
                    }, 
                    "name": "Springfield Regional Medical Center"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Westerville", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43081"
                    }, 
                    "name": "Saint Ann's Hospital"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John P. Kuebler", 
                    "phone": "614-566-3275"
                }, 
                "facility": {
                    "address": {
                        "city": "Zanesville", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43701"
                    }, 
                    "name": "Genesis HealthCare System"
                }, 
                "investigator": {
                    "last_name": "John P. Kuebler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "julie-traylor@ouhsc.edu", 
                    "last_name": "Robert S. Mannel", 
                    "phone": "405-271-4272"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "University of Oklahoma Health Sciences Center"
                }, 
                "investigator": {
                    "last_name": "Robert S. Mannel", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "julie-traylor@ouhsc.edu", 
                    "last_name": "Robert S. Mannel", 
                    "phone": "405-271-4272"
                }, 
                "facility": {
                    "address": {
                        "city": "Tulsa", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "74146"
                    }, 
                    "name": "Tulsa Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Robert S. Mannel", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Parviz Hanjani", 
                    "phone": "215-481-2402"
                }, 
                "facility": {
                    "address": {
                        "city": "Abington", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19001"
                    }, 
                    "name": "Abington Memorial Hospital"
                }, 
                "investigator": {
                    "last_name": "Parviz Hanjani", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul A. DiSilvestro", 
                    "phone": "401-274-1122"
                }, 
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02905"
                    }, 
                    "name": "Women and Infants Hospital"
                }, 
                "investigator": {
                    "last_name": "Paul A. DiSilvestro", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alpa M. Nick", 
                    "phone": "713-792-3245"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "M D Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Alpa M. Nick", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer", 
        "other_outcome": [
            {
                "description": "Mutations of genes in the MAPK and PI3K/AKT/mTOR pathways will be analyzed. Done using one-sided tests with alpha=0.05.", 
                "measure": "Mutations of genetic pathways (translational research)", 
                "safety_issue": "No", 
                "time_frame": "Up to day 1 of course 3"
            }, 
            {
                "description": "Protein levels of ER, PR, pERK, and DUSP6 will be analyzed. Done using one-sided tests with alpha=0.05.", 
                "measure": "Changes in protein levels (translational research)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to up to day 1 of course 3"
            }, 
            {
                "description": "Done using one-sided tests with alpha=0.05.", 
                "measure": "Transcriptional signatures by RNAseq in predicting MEK addiction and sensitivity to trametinib (translational research)", 
                "safety_issue": "No", 
                "time_frame": "Up to day 1 of course 3"
            }, 
            {
                "description": "Done using one-sided tests with alpha=0.05.", 
                "measure": "Proteins in cell-free DNA in plasma (translational research)", 
                "safety_issue": "No", 
                "time_frame": "Up to day 1 of course 3"
            }, 
            {
                "description": "The association between KRAS TR endpoints will be explored using Cox proportional hazards models.", 
                "measure": "Presence of KRAS mutations (translational research)", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "Plasma-time concentration data trametinib will be displayed in tables and/or graphs. Population pharmacokinetic parameters of trametinib and combination therapies such as clearance (CL) and volume of distribution (V) will be determined. In addition, the influence of various covariates (e.g. age, weight, and race) on the pharmacokinetic parameters will be examined.", 
                "measure": "Pharmacokinetic parameters of trametinib (translational research)", 
                "safety_issue": "No", 
                "time_frame": "Days 15, 29, and 55"
            }
        ], 
        "overall_official": {
            "affiliation": "NRG Oncology", 
            "last_name": "David Gershenson", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be grouped by their randomized treatment for intention-to-treat analyses (ITT).", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "Time from study entry to time of progression or death, whichever occurs first, assessed up to 10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The severity of each AE will be assessed. Patients will be tabulated according to their maximum severity for each organ system or preferred term. Summarized with descriptive statistics for the patients in the safety analysis dataset.", 
                "measure": "Adverse events (AEs) assessed using the National Cancer Institute (NCI) CTCAE version 4", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "Based on a log-rank test. Characterized by treatment group with Kaplan-Meier plots and estimates of the median time until death. The log rank test will be used to compare treatment groups with respect to overall survival.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Time from study entry to time of death or date of last contact, assessed up to 10 years"
            }, 
            {
                "description": "Compared between the arms using logistic regression via a model incorporating study arm and the factors used in the minimization algorithm. The p-value associated with study arm will be obtained from this model. An 80% confidence interval for the odds ratio will be provided.", 
                "measure": "Objective tumor response rate (complete response and partial response) using the RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 years"
            }, 
            {
                "description": "Examined with a mixed model, adjusting for pretreatment TOI score, age, and treatment option (PLD, weekly topotecan hydrochloride, or weekly paclitaxel). The overall type I error for the two primary quality of life (QoL) hypotheses (1 and 2) will be controlled at alpha=0.10 by using a Bonferroni adjustment: each will be tested at alpha=0.0513. The overall alpha for the QoL hypotheses will be controlled by testing the secondary hypothesis only if one or both of the two primary hypotheses are rejected.  All tests will be two-sided.", 
                "measure": "Quality of life as measured by FACT and FACT-NTX", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}